Clinical Trial Detail

NCT ID NCT01903330
Title ERC1671/GM-CSF/Cyclophosphamide for the Treatment of Glioblastoma Multiforme
Recruitment Recruiting
Gender both
Phase Phase II
Variant Requirements No
Sponsors Daniela A. Bota
Indications

glioblastoma multiforme

malignant glioma

gliosarcoma

Therapies

Bevacizumab

Cyclophosphamide

Sargramostim

Age Groups: adult

No variant requirements are available.